Bifidobacterium longum subsp. longum 51A attenuates intestinal injury against irinotecan-induced mucositis in mice

Quintanilha, Mônica F.; Miranda, Vivian C.; Souza, Ramon O.; Gallotti, Bruno; Cruz, Clênio Silva; Santos, Elândia Aparecida; Alvarez-Leite, Jacqueline I; Jesus, Luís Cláudio Lima de; Azevedo, Vasco; Trindade, Luísa Martins; Cardoso, Valbert Nascimento; Ferreira, Ênio; Carvalho, Bárbara Andrade de; Soares, Pedro Marcos Gomes; Vieira, Angélica T.; Nicoli, Jacques Robert; Martins, Flaviano S.

doi:10.1016/j.lfs.2021.120243

Cited by 20 publications

(15 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, the increased abundance of Bifidobacterium longum subsp. Longum in the IBD samples may be attributed to host-responsive mechanisms against gut inflammation since this species has been demonstrated to possess strong antioxidant capacity [ 26 ], attenuate intestinal injury [ 27 ], and generally protect against IBD [ 28 ]. Alterations in the bacteria population is also linked with patients’ response to treatment as demonstrated by studies such as Dovrolis et al [ 29 ], which reported that Infliximab treatment has a notable impact on both the gut microbial composition and the inflamed tissue transcriptome in IBD patients [ 29 ].…”

Section: Discussionmentioning

confidence: 99%

The gut metagenomics and metabolomics signature in patients with inflammatory bowel disease

Ocansey

Hang

et al. 2022

Gut Pathog

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD), a chronic gut immune dysregulation and dysbiosis condition is rapidly increasing in global incidence. Regardless, there is a lack of ideal diagnostic markers, while conventional treatment provides scarce desired results, thus, the exploration for better options. Changes in the gut microbial composition and metabolites either lead to or are caused by the immune dysregulation that characterizes IBD. This study examined the fecal metagenomics and metabolomic changes in IBD patients. A total of 30 fecal samples were collected from 15 IBD patients and 15 healthy controls for 16S rDNA gene sequencing and UHPLC/Q-TOF-MS detection of metabolomics. Results showed that there was a severe perturbation of gut bacteria community composition, diversity, metabolites, and associated functions and metabolic pathways in IBD. This included a significantly decreased abundance of Bacteroidetes and Firmicutes, increased disease-associated phyla such as Proteobacteria and Actinobacteria, and increased Escherichiacoli and Klebsiellapneumoniae in IBD. A total of 3146 metabolites were detected out of which 135 were differentially expressed between IBD and controls. Metabolites with high sensitivity and specificity in differentiating IBD from healthy individuals included 6,7,4′-trihydroxyisoflavone and thyroxine 4′-o-.beta.-d-glucuronide (AUC = 0.92), normorphine and salvinorin a (AUC = 0.90), and trichostachine (AUC = 0.91). Moreover, the IBD group had significantly affected pathways including primary bile acid biosynthesis, vitamin digestion and absorption, and carbohydrate metabolism. This study reveals that the combined evaluation of metabolites and fecal microbiome can be useful to discriminate between healthy subjects and IBD patients and consequently serve as therapeutic and diagnostic targets.

show abstract

Section: Discussionmentioning

confidence: 99%

The gut metagenomics and metabolomics signature in patients with inflammatory bowel disease

Ocansey

Hang

et al. 2022

Gut Pathog

View full text Add to dashboard Cite

show abstract

“…Although some preclinical studies report the host’s beneficial effects related to “live” probiotics consumption [ 16 , 17 , 18 , 19 , 20 ], there are many questions regarding their safety concerns in clinical practice, especially in premature infants or immune-compromised patients. In these conditions, probiotics can translocate into the blood system and increase the risk of systemic infections [ 21 , 22 , 23 , 24 ].…”

Section: Introductionmentioning

confidence: 99%

Paraprobiotics and Postbiotics of Lactobacillus delbrueckii CIDCA 133 Mitigate 5-FU-Induced Intestinal Inflammation

et al. 2022

Self Cite

View full text Add to dashboard Cite

Intestinal mucositis is a commonly reported side effect in oncology practice. Probiotics are considered an excellent alternative therapeutic approach to this debilitating condition; however, there are safety questions regarding the viable consumption of probiotics in clinical practice due to the risks of systemic infections, especially in immune-compromised patients. The use of heat-killed or cell-free supernatants derived from probiotic strains has been evaluated to minimize these adverse effects. Thus, this work evaluated the anti-inflammatory properties of paraprobiotics (heat-killed) and postbiotics (cell-free supernatant) of the probiotic Lactobacillus delbrueckii CIDCA 133 strain in a mouse model of 5-Fluorouracil drug-induced mucositis. Administration of paraprobiotics and postbiotics reduced the neutrophil cells infiltrating into the small intestinal mucosa and ameliorated the intestinal epithelium architecture damaged by 5-FU. These ameliorative effects were associated with a downregulation of inflammatory markers (Tlr2, Nfkb1, Il12, Il17a, Il1b, Tnf), and upregulation of immunoregulatory Il10 cytokine and the epithelial barrier markers Ocln, Cldn1, 2, 5, Hp and Muc2. Thus, heat-killed L. delbrueckii CIDCA 133 and supernatants derived from this strain were shown to be effective in reducing 5-FU-induced inflammatory damage, demonstrating them to be an alternative approach to the problems arising from the use of live beneficial microorganisms in clinical practice.

show abstract

“…Bifidobacterium longum 5 1A reduced the daily disease activity index, protected the intestinal architecture, preserved the length of the intestine, and reduced intestinal permeability, inflammation, and oxidative damage induced by irinotecan in a murine model of mucositis, suggesting its potential as a probiotic therapy for mucositis [64 ▪ ]. These findings are consistent with an earlier study on selenium enriched Bifidobacterium longum , which prevented symptoms of mucositis including mortality, weight loss, diarrhea, and inflammation following irinotecan administration in mice [65].…”

Section: Probioticsmentioning

confidence: 99%

Nonpharmacological approaches for improving gut resilience to chemotherapy

Bullard¹,

McDonald²,

Cardaci³

et al. 2022

Current Opinion in Supportive &Amp; Palliative Care

View full text Add to dashboard Cite

Purpose of reviewMucositis of the gastrointestinal tract is a debilitating side effect of chemotherapy that negatively influences treatment tolerance and patient life quality. This review will evaluate the recent literature on nonpharmacological strategies that have the potential to improve chemotherapy-induced mucositis (CIM).Recent findingsAlternatives to pharmacological approaches have shown great promise in preventing CIM. Natural products, including curcumin, ginseng, quercetin, and patchouli all show potential in mitigating CIM. In addition, dietary patterns, such as the elemental diet, high fiber diet, and diets high in amino acids have documented benefits in preventing CIM. Perhaps the greatest advancement coming to this arena in recent years is in the field of probiotics. Indeed, research on single species as well as probiotic mixtures show potential in reducing CIM insofar as probiotics are now being suggested for treatment of CIM by governing bodies. Although behavioral interventions including psychological interventions and exercise interventions have shown promise in reducing cancer therapy-related side effects, more work in this domain is warranted and particularly in the context of CIM.SummaryAlternatives to pharmacological approaches show great potential for use in prevention and treatment of CIM and should be further developed for use in the clinic.

show abstract

Bifidobacterium longum subsp. longum 51A attenuates intestinal injury against irinotecan-induced mucositis in mice

Cited by 20 publications

References 46 publications

The gut metagenomics and metabolomics signature in patients with inflammatory bowel disease

The gut metagenomics and metabolomics signature in patients with inflammatory bowel disease

Paraprobiotics and Postbiotics of Lactobacillus delbrueckii CIDCA 133 Mitigate 5-FU-Induced Intestinal Inflammation

Nonpharmacological approaches for improving gut resilience to chemotherapy

Contact Info

Product

Resources

About